Aurobindo Pharma Ltd. reported a 4% decline in its consolidated net profit to ₹532.45 crore for the quarter ended March as against ₹554.77 crore in the year-earlier period. Total revenue from operations decreased by 2.8% to ₹3,641.63 crore (₹3,745.92 crore). For FY’17, net profit rose 13.6% to ₹2,301.67 crore (₹2,025.09 crore).Total revenue from operations increased by 8.13% to ₹15,089.86 crore (₹13,955.22 crore). N. Govindarajan, managing director, Aurobindo Pharma said the revenue growth came despite a challenging environment in select markets. “We continue to invest in building a differentiated and speciality product portfolio, which will sustain the growth momentum for the future,” he said. The board of director has approved a second interim dividend of ₹1.25 per equity share (face value of ₹1). The results were announced on Monday after trading hours. On Tuesday, the shares of the company gained 12.94% to close at ₹580.15 apiece.
This is a Premium article available exclusively to our subscribers. To read 250+ such premium articles every
month
You have exhausted your free article limit.
Please support quality journalism.
You have exhausted your free article limit.
Please support quality journalism.
The Hindu operates by its editorial values to provide you quality journalism.
You have read {{data.cm.views}} out of {{data.cm.maxViews}} free articles.
This is your last free article.